Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site
SHANGHAI, June 20, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing
1st production of pharmaceutical grade egg and milk challenge meals Product portfolio of challenge meals now includes peanut, milk and egg Innovation pipeline includes development of 'Top 9' allergen products as well as a products suitable from 6...
QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines
SHANGHAI, June 5, 2025 /PRNewswire/ -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately USD 14 million) and was led exclusively...
AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT designation expected to expedite development; 72 weeks interim clinical trial data showing sustainable reduction of TTR over 90% with no significant adverse events. SUZHOU, China, May 29, 2025 /PRNewswire/ -- AccurEdit Therapeutics today...
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND)...
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
HONG KONG, March 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical trial...
AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application
HONG KONG, Feb. 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for...
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2026. Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding...